Florida Cancer Specialists & Research Institute | Strategic Alliance Partners

January 21, 2024

Robin Marshall's "most valuable" painting was recently purchased by her oncologist, Alpana Desai, MD, of Florida Cancer Specialists & Research Institute.

January 19, 2024

The Florida Cancer Specialists & Research Institute, LLC 2022 Annual Report has been recognized in the 4th Annual Healthcare Digital Marketing Awards.

January 17, 2024

The value-based care program offers Florida patients access to high quality cancer care while reducing costs for employers

January 15, 2024

Florida Cancer Specialists & Research Institute physicians were recognized in 2023 by several magazines as top doctors in their local communities.

January 13, 2024

Florida Cancer Specialists & Research Institute, LLC is pleased to welcome radiation oncologist Bradford Perez, MD to the statewide practice.

January 11, 2024

Drs Monk and Tarantino highlight current research investigating B7-H4–directed antibody-drug conjugates. in multiple solid tumor types.

January 11, 2024

National Family Caregivers Month is observed every November to honor the contributions and sacrifices caregivers make to support their loved ones.

January 08, 2024

Florida Cancer Specialists & Research Institute, LLC announced the promotion of two members of its executive and physician leadership team.

January 05, 2024

Medical oncologist Lucio N. Gordan MD, president and managing physician of Florida Cancer Specialists & Research Institute, LLC, is lead author of the first real-world study comparing the two preferred regimens recommended for the primary treatment of non-transplant patients with newly-diagnosed multiple myeloma, published recently in Science Direct.

January 02, 2024

Padmaja Sai, MD, medical oncologist and hematologist with Florida Cancer Specialists & Research Institute, was presented last week with the AdventHealth Foundation 2023 Humanitarian of the Year Award.

January 01, 2024

During the 2023 Florida Society of Clinical Oncology Fall Session, several Florida Cancer Specialists & Research Institute, LLC, physicians were elected to serve as executive committee officers and chairs for the nationally recognized advocacy group in the upcoming term.

December 26, 2023

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that hematologist and medical oncologist Andrea Katz, MD has joined the statewide practice.

December 05, 2023

A best practice clinical program developed by Florida Cancer Specialists & Research Institute, LLC is ensuring that patients with certain blood disorders achieve maximum clinical benefits from the use of oral medications.

December 03, 2023

Florida Cancer Specialists & Research Institute, LLC has appointed medical oncologist and hematologist Richard McDonough, MD as Director of Patient Advocacy for the statewide practice.

December 02, 2023

Florida Cancer Specialists & Research Institute, LLC is now offering an advanced maintenance therapy program that slows the progression of relapsed/refractory multiple myeloma.

December 01, 2023

Innovative new technologies being used exclusively by Florida Cancer Specialists & Research Institute, LLC in Ocala and The Villages are helping to target tumors more precisely, reduce side effects and enhance comfort for patients receiving radiation therapy for the treatment of certain cancers, including breast cancer and head and neck cancers.

November 23, 2023

Research conducted by Florida Cancer Specialists & Research Institute, LLC recently confirmed the effectiveness of a new medication in protecting bone marrow of patients who receive chemotherapy for extensive-stage small cell lung cancer.

November 04, 2023

Florida Cancer Specialists & Research Institute physicians will present at the Society for Immunotherapy of Cancer Annual Meeting this week in San Diego.

October 31, 2023

Two novel antibody-drug conjugates, HS-20089 and SGN-B7H4V, targeting the highly expressed immune checkpoint ligand B7-H4 have demonstrated manageable safety profiles and shown anti-tumor activity in first-in-human dose-escalation portions of phase 1 trials and will move forward to the next portions of the studies.

October 19, 2023

Cancer patients who receive molecular testing results prior to beginning first-line treatment for metastatic nonsquamous non-small cell lung cancer appear to live longer.